Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Many patients with HR+, HER2− early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few ye...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Johnston, Stephen R. D., Harbeck, Nadia, Hegg, Roberto, Toi, Masakazu, Martin, Miguel, Shao, Zhi Min, Zhang, Qing Yuan, Martinez Rodriguez, Jorge Luis, Campone, Mario, Hamilton, Erika, Sohn, Joohyuk, Guarneri, Valentina, Okada, Morihito, Boyle, Frances, Neven, Patrick, Cortés, Javier, Huober, Jens, Wardley, Andrew, Tolaney, Sara M., Cicin, Irfan, Smith, Ian C., Frenzel, Martin, Headley, Desirée, Wei, Ran, San Antonio, Belen, Hulstijn, Maarten, Cox, Joanne, O’Shaughnessy, Joyce, Rastogi, Priya
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2020
主題:
RAPID COMMUNICATIONS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768339/
https://ncbi.nlm.nih.gov/pubmed/32954927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02514
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料